Skip to main content
. 2022 May 27;14(11):2668. doi: 10.3390/cancers14112668

Figure 2.

Figure 2

Persistent tumor following CRT. (a) Pre-treatment axial fused FDG PET-CT demonstrates a hypermetabolic tumor in the mid-esophagus (white arrowhead); (b) Axial fused FDG PET-CT image 12 weeks following completion of CRT demonstrates persistent, although improved, hypermetabolic soft tissue mass in the mid-esophagus (white arrowhead). Biopsy confirmed the presence of persistent viable tumor.